INDICATIONS AND RESULTS OF KIDNEY TUMOR NEEDLE ABLATION

Czech version

Authors: Jeffrey A. Cadeddu; Md
Authors‘ workplace: Department of Urology, UT Southwestern Medical Center
Published in: Urol List 2011; 9(4): 54-57

Overview

Since the introduction of kidney radiofrequency ablation in 1997, indications for the procedure have greatly expanded. Traditionally reserved for elderly patients with significant medical comorbidities who were poor surgical candidates, contemporary indications may additionally include elective use in solitary kidneys, transplant kidneys, metastatic renal cell carcinoma, and healthy patients among others. We herein review the evidence supporting the role of RFA for renal tumor ablation across a wide range of clinical settings.

Key words:
radiofrequency ablation, renal mass, RCC

Sources

1. Sun M, Thuret R, Abdollah F et al. Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend Analysis. Eur Urol 2011; 59(1): 135–141.

2. Chen DY, Uzzo RG. Evaluation and management of the renal mass. Med Clin North Am 2010; 95(1): 179–189.

3. Novick AC, Campbell SC, Belledegrun A et al. Guideline for management of the Clinical Stage 1 renal mass. 2009: cited 12/10/2010. Available from: <http:// www.auanet.org/content/media/renalmass09.pdf>

4. Hong K, Georgiades C. Radiofrequency ablation: mechanism of action and devices. J Vasc Interv Radiol 2010; 21 (8 Suppl): S179–186.

5. Schulman CC, Zlotta AR. Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: early clinical experience. Urology 1995; 45(1): 28–33.

6. Zlotta AR, Raviv G, Peny MO et al. [A new method of cancer treatment: the use of radiofrequencies in urological tumors]. Acta Urol Belg 1996; 64(1): 1–5.

7. Zlotta AR, Wildschutz T, Raviv G et al. Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol 1997; 11(4): 251–258.

8. Raman JD, Hall DW, Cadeddu JA. Renal ablative therapy: radiofrequency ablation and cryoablation. J Surg Oncol 2009; 100(8): 639–644.

9. Kader AK, Tamboli P, Luongo T et al. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol 2007; 177(3): 855–860.

10. Roos FC, Pahernik S, Melchior SW et al. Renal tumour surgery in elderly patients. BJU Int 2008; 102(6): 680–683.

11. Takao T, Tsujimura A, Kiuchi H et al. Urological surgery in patients aged 80 years and older: a 30-year retrospective clinical study. Int J Urol 2008; 15(9): 789–793.

12. Roos FC, Hampel C, Thuroff JW. Renal cancer surgery in the elderly. Curr Opin Urol 2009; 19(5): 459–464.

13. Levinson AW, Su LM, Agarwal D et al. Long-term oncological and overall outcomes of percutaneous radio frequency ablation in high risk surgical patients with a solitary small renal mass. J Urol 2008; 180(2): 499–504.

14. McDougal WS, Gervais DA, McGovern FJ et al. Long-term followup of patients with renal cell carcinoma treated with radio frequency ablation with curative intent. J Urol 2005; 174(1): 61–63.

15. Pavlovich CP, Walther MM, Choyke PL et al. Percutaneous radiofrequency ablation of small renal tumors: initial results. J Urol 2002; 167(1): 10–15.

16. Hwang JJ, Walther MM, Pautler SE et al. Radiofrequency ablation of small renal tumors: intermediate results. J Urol 2004; 171(5): 1814–1818.

17. Park BK, Kim CK. Percutaneous radiofrequency ablation of renal tumors in patients with von Hippel-Lindau disease: preliminary results. J Urol 2010; 183(5): 1703–1707.

18. Krambeck AE, Farrell MA, Callstrom MR et al. Radiofrequency ablation of renal tumors in the solitary kidney. Can J Urol 2008; 15(4): 4163–4168.

19. Mylona S, Kokkinaki A, Pomoni M et al. Percutaneous radiofrequency ablation of renal cell carcinomas in patients with solitary kidney: 6 years experience. Eur J Radiol 2009; 69(2): 351–356.

20. Prevoo W, van den Munckhof MP, Meinhardt W et al. Radiofrequency ablation of kidney tumours in patients with a solitary kidney. Clin Radiol 2010; 65(3): 230–236.

21. Raman JD, Raj GV, Lucas SM et al. Renal functional outcomes for tumours in a solitary kidney managed by ablative or extirpative techniques. BJU Int 2010; 105(4): 496–500.

22. Raman JD, Thomas J, Lucas SM et al. Radiofrequency ablation for T1a tumors in a solitary kidney: promising intermediate oncologic and renal function outcomes. Can J Urol 2008; 15(2): 3980–3985.

23. Syvanthong C, Wile GE, Zagoria RJ. Effect of radiofrequency ablation of renal tumors on renal function in patients with a solitary kidney. AJR Am J Roentgenol 2007; 188(6): 1619–1621.

24. Matevossian E, Novotny A, Vogelsang B et al. Noninvasive therapy of incidental de novo renal cell carcinoma in a kidney allograft 12 years after transplantation: report of a case and review of literature. Transplant Proc 2008; 40(4): 915–917.

25. Veltri A, Grosso M, Castagneri F et al. Radiofrequency thermal ablation of small tumors in transplanted kidneys: an evolving nephron-sparing option. J Vasc Interv Radiol 2009; 20(5): 674–679.

26. Aron M, Hegarty NJ, Remer E et al. Percutaneous radiofrequency ablation of tumor in transplanted kidney. Urology 2007; 69(4): 778 e5–7.

27. Baughman SM, Sexton WJ, Glanton CW et al. Computerized tomography guided radio frequency ablation of a renal cell carcinoma within a renal allograft. J Urol 2004; 172 (4 Pt 1): 1262–1263.

28. Charboneau JW, O'Loughlin MT, Milliner DS et al. Sonographically guided percutaneous radio frequency ablation of a renal cell carcinoma in a transplanted kidney. J Ultrasound Med 2002; 21(11): 1299–1302.

29. Goeman L, Joniau S, Oyen R et al. Percutaneous ultrasound-guided radiofrequency ablation of recurrent renal cell carcinoma in renal allograft after partial nephrectomy. Urology 2006; 67(1): 199.

30. Kozma V, Vegso GY, Deak PA et al. Radiofrequency ablation of an intercalyceal neoplasm in a transplanted kidney using percutaneous nephrostomy for cooling – safety and early result. Interv Med Appl Sci 2010: 2: 37–41.

31. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345(23): 1655–1659.

32. Mickisch GH, Garin A, van Poppel H et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358(9286): 966–970.

33. Sun M, Lughezzani G, Perrotte P et al. Treatment of metastatic renal cell carcinoma. Nat Rev Urol 2010; 7(6): 327–338.

34. Karam JA, Ahrar K, Wood CG et al. Radio frequency ablation of renal tumors in patients with meta-static renal cell carcinoma. J Urol 2010; 184(5): 1882–1887.

35. Krambeck AE, Leibovich BC, Lohse CM et al. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol 2006; 176(5): 1990–1995.

36. Stern JM, Gupta A, Raman JD et al. Radiofrequency ablation of small renal cortical tumours in healthy adults: renal function preservation and intermediate oncological outcome. BJU Int 2009: 104(6); 786–789.

37. Kirkham AP, Ho SG, Paterson RF et al. Treatment of a juxtaglomerular tumour with radiofrequency ablation. Urology 2008; 71(1): 168 e1–4.

38. Brown SD, Vansonnenberg E, Morrison PR et al. CT-guided radiofrequency ablation of pediatric Wilms tumor in a solitary kidney. Pediatr Radiol 2005; 35(9): 923–928.

39. Zagoria RJ. Percutaneous image-guided radiofrequency ablation of renal malignancies. Radiol Clin North Am 2003: 41: 1067–1075.